14901-96-3

Upstream product

• 681448-78-2 N-(isoquinolin-4-yl)benzamide 
• 93-97-0 benzoic acid anhydride 
• 1532-97-4 4-bromoisoquinoline 
• 23687-25-4 4-aminoisoquinoline 

Downstream Products

• 681448-81-7 4-amino-1,2,3,4-tetrahydroisoquinoline 
• 53667-22-4 2-benzyl-1,2,3,4-tetrahydroisoquinolin-4-amine 

Relevant academic research and scientific papers

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

A Unified Synthesis of Bifunctional 4-Substituted-1,2,3,4-tetrahydroisoquinoline Derivatives

Starting from a single, commercially available bromoisoquinoline, convenient (multigram) syntheses of 4-substituted-1,2,3, 4-tetrahydroisoquinoline derivatives have been developed. The compounds thus prepared show suitable substitution patterns for further derivatization and constitute a new family of compounds of potential pharmacological interest.